Amita Gupta, MD

CRS:

BJMCJHU

Role:

Investigators

Position:

Principal Investigator, Associate Professor and Deputy Director, CCGHE

Email:

agupta25@jhmi.edu

Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Associate Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in international health at the JH Bloomberg School of Public Health.

Board certified by the American Board of Internal Medicine in internal medicine and infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, and tuberculosis (TB). Since 2002, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations, including the C-TRIUMPH and RePORT consortium for tuberculosis (TB) research funded by the US National Institutes of Health (NIH) and the government of India. Dr. Gupta is also Co-principal Investigator of the NIH-funded Baltimore-Washington-India (BWI) HIV and Infectious Diseases Clinical Trials Unit (CTU), and she is an active clinical investigator in multi-country HIV/TB trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT). Additionally, she has been awarded research grants from the NIH, CDC, and several philanthropic foundations to investigate TB in children and pregnant women, malnutrition, infection and inflammation, HIV treatment outcomes, and antibiotic resistance.

Dr. Gupta is an author of more than 80 peer-reviewed research publications and 7 book chapters, primarily on prevention and treatment of HIV, TB, and bacterial infections, predominantly in low- and middle-income settings. She has also mentored more than 30 junior scientists in India to run research studies and submit their own scientific findings to peer-reviewed publications.

From 2000–2002, Dr. Gupta worked for the US Centers for Disease Control and Prevention (CDC), where she was engaged in global public health projects in Guatemala, Vietnam, and Micronesia.

Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Masters in Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention and at the JHU School of Medicine.

  • Chair, IMPAACT P1078
  • Co-chair ACTG 5274
  • Vice-chair ACTG 5279
  • Co-chair ACTG 5300/IMPAACT 2005 Phoenix preparation study and main trial
  • Vice-chair, IMPAACT TB Scientific Committee
  • Investigator, Tuberculosis Transformative Science Group
  • Member, Clinical Management Committee, IMPAACT PROMISE P1077
  • Co-Investigator IMPAACT P1026s and IMPAACT P2001
  • Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study. International Journal of Tuberculosis and Lung Disease. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882 
  • Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, MBBCh, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A, for the Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. The Lancet. 2016;387(10024). 
  • Mave V, Erlandson KM, Gupte N, Balgopal A, Asmuth DM, Campbell TB, Smeaton L, Kumarasamy N, Hakim J, Santos B, Riviere C, Hosseinipour MC, Sugandhavesa P, Infante R, Pillay S, Cardoso SW, Tripathy S, Mwelase N, Berendes S, Andrade BB, Thomas DL, Bollinger RC, Gupta A, and the ACTG PEARLS and NWCS 319 Study Team. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. J Infect Dis. 2016 Apr 1;213(7). doi: 10.1093/infdis/jiw096 First published online: March 8, 2016.
  • Gupta A, Montepiedra G, Gupte A, Jubulis J, Zeldow B, Detrick B, Violari A, Madhi SA, Bobat R, Cotton MF, Mitchell C, Spector SA, for the IMPAACT NWCS113 and P1041 Study Team. Low Vitamin-D levels combined with PKP3-SIGIRR-TMEM16J host variants is strongly associated with tuberculosis and death in HIV-infected and -exposed infants. PLOS ONE. 2016 Feb 12;11(2):e0148649. doi: 10.1371/journal.pone.0148649. eCollection 2016
  • Mathad J, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N, Gupte N, Joshi S, Chandanwale A, Dupnik K, Kulkarni V, Deshpande P, Fitzgerald D, Gupta A. Quantitative IFN-γ,IL-2 response and latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med. 2016 Jan 14. [Epub ahead of print].
  • Kapoor S, Gupta A, Shah M. Cost effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016:20(1).
  • Maddali MV, Dowdy DW, Gupta A, Shah M. Economic and epidemiological impact of early antiretroviral therapy initiation in India. Journal of the International AIDS Society. 2015;18:20217.
  • Balagopal A, Asmuth DM, Yang W-T, Campbell T, Gupte N, Smeaton L, Kanyama C, Grinsztejn B, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Li X-D, Pollard RB, Semba RD, Thomas DL, Bollinger RC, Gupta A. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in m Multinational case-cohort study. J Acquir Immune Def Syndr. 2015 Oct 1.
  • Suryavanshi N, Mave V, Gupte N, Bhosale R, Sambarey P, Patil S, Sastry J, Bollinger R, Gupta A, Shankar A & The SWEN India Study Team. Contraceptive use and factors associated with postpartum surgical sterilization among HIV-infected women in Pune, India. Journal of HIV/AIDS & Social Services. 2015;14(3):21 Aug [Epub ahead of print] DOI:10.1080/15381501.2014.946548
  • Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;16 Jun. pii: civ464. [Epub ahead of print]

Categories

Leadership Committees
CRS
Roles

Clinical Trials

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More